Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
656 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05896566 | A Window-of-Opportunity Trial of Giredestrant +/- Triptorelin vs. Anastrozole + Triptorelin in Premenopausal Patients With ER-positive/HER2-negative Early Breast Cancer(PREcoopERA) | completed | Phase 2 | 231 | ETOP IBCSG Partners FoundationNETWORK | 6 | Feb 24, 2026 | clinicaltrials |
| NCT02677922 | A Study to Assess the Safety and Efficacy of Two Combinations of Isocitrate Dehydrogenase (IDH) Mutant Targeted Therapies Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) Harboring IDH Mutations Who Are Not Candidates to Receive Intensive Induction Chemotherapy | active not recruiting | Phase 1 / Phase 2 | 130 |
| CelgeneINDUSTRY |
| 14 |
| Feb 19, 2026 |
| clinicaltrials |
| NCT05987332 | IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma | active not recruiting | Phase 2 / Phase 3 | 420 | IDEAYA BiosciencesINDUSTRY | 13 | Feb 17, 2026 | clinicaltrials |
| NCT07263438 | Efficacy of the Combination of Trimipramine and Atezolizumab With Bevacizumab in Patients With Recurrent Glioblastoma: a Phase 2 Trial(Phenix) | recruiting | Phase 2 | 59 | Centre Hospitalier Universitaire VaudoisOTHER | 1 | Feb 13, 2026 | clinicaltrials |
| NCT02394626 | Surgery for Recurrent Glioblastoma(RESURGE) | recruiting | Phase 2 | 120 | Insel Gruppe AG, University Hospital BernOTHER | 9 | Feb 2, 2026 | clinicaltrials |
| NCT03740529 | A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL | completed | Phase 1 / Phase 2 | 803 | Loxo Oncology, Inc.INDUSTRY | 10 | Jan 27, 2026 | clinicaltrials |
| NCT04630730 | Intravesical Recombinant BCG Followed by Perioperative Chemo-immunotherapy for Patients With MIBC | active not recruiting | Phase 2 | 46 | Swiss Cancer InstituteOTHER | 1 | Jan 21, 2026 | clinicaltrials |
| NCT05601973 | Amivantamab, Lazertinib and Bevacizumab in Patients With EGFR-mutant Advanced Non-small Cell Lung Cancer With Progression on Previous Third-generation EGFR-TKI(AMAZE-lung) | active not recruiting | Phase 2 | 60 | ETOP IBCSG Partners FoundationNETWORK | 6 | Jan 21, 2026 | clinicaltrials |
| NCT03937843 | Reduced Intensity Radio-chemotherapy for Stage IIA/B Seminoma | active not recruiting | Phase 2 | 135 | Swiss Cancer InstituteOTHER | 2 | Jan 20, 2026 | clinicaltrials |
| NCT05529316 | A Study of Botensilimab (AGEN1181) for the Treatment of Advanced Melanoma | active not recruiting | Phase 2 | 150 | Agenus Inc.INDUSTRY | 10 | Jan 16, 2026 | clinicaltrials |
| NCT01808599 | Phase II Study of Chlorambucil and Subcutaneous Rituximab in Patients With Extranodal MALT Lymphoma | active not recruiting | Phase 2 | 112 | International Extranodal Lymphoma Study Group (IELSG)OTHER | 3 | Jan 15, 2026 | clinicaltrials |
| NCT03708003 | Ibrutinib lead-in Followed by Venetoclax Plus Ibrutinib in Patients With RR CLL | terminated | Phase 2 | 30 | Swiss Cancer InstituteOTHER | 1 | Dec 30, 2025 | clinicaltrials |
| NCT03993678 | Intratumoral Injection of IP-001 Following Thermal Ablation in Patients With Advanced Solid Tumors. | completed | Phase 1 / Phase 2 | 28 | Swiss Cancer InstituteOTHER | 1 | Dec 30, 2025 | clinicaltrials |
| NCT04604067 | Assessing a ctDNA and PET-oriented Therapy in Patients With DLBCL A Multicenter, Open-label, Phase II Trial. | active not recruiting | Phase 2 | 260 | Swiss Cancer InstituteOTHER | 2 | Dec 30, 2025 | clinicaltrials |
| NCT06452394 | NEODOXy: Targeting Breast Cancer Stem Cells With Doxycycline | recruiting | Phase 2 | 50 | Swiss Cancer InstituteOTHER | 1 | Dec 30, 2025 | clinicaltrials |
| NCT06835049 | Feasibility of Total Neoadjuvant Treatment With HYPErthermia in Patients With High-risk Extremity and Trunk Soft Tissue Sarcoma (TNT-HYPE)(TNT-HYPE) | recruiting | Phase 2 | 24 | Swiss Cancer InstituteOTHER | 1 | Dec 30, 2025 | clinicaltrials |
| NCT06680050 | Phase II Study of Radiotherapy Followed by Durvalumab and Ceralasertib in Stage III NSCLC Patients With Thoracic Relapses +/- Oligometastases After PACIFIC Regimen(AUSTRAL) | recruiting | Phase 2 | 21 | Mario Negri Institute for Pharmacological ResearchOTHER | 2 | Dec 18, 2025 | clinicaltrials |
| NCT05342636 | A Study of Combination Therapies With or Without Pembrolizumab (MK-3475) and/or Chemotherapy in Participants With Advanced Esophageal Cancer (MK-3475-06A) | completed | Phase 1 / Phase 2 | 90 | Merck Sharp & Dohme LLCINDUSTRY | 13 | Dec 17, 2025 | clinicaltrials |
| NCT06102057 | PACCELIO - FDG-PET Based Small Volume Accelerated Immuno Chemoradiotherapy in Locally Advanced NSCLC(PACCELIO) | recruiting | Phase 2 | 110 | TheraOpOTHER | 2 | Dec 17, 2025 | clinicaltrials |
| NCT03774082 | Activity, Safety and Pharmacokinetics in Pediatric Subjects With Moderate and Severe Chronic Graft vs. Host Disease After Allogeneic Stem Cell Transplant(REACH 5) | completed | Phase 2 | 46 | Novartis PharmaceuticalsINDUSTRY | 14 | Dec 11, 2025 | clinicaltrials |
| NCT04381650 | A Study of TAK-981 Given With Pembrolizumab in Participants With Select Advanced or Metastatic Solid Tumors | completed | Phase 1 / Phase 2 | 161 | TakedaINDUSTRY | 9 | Dec 10, 2025 | clinicaltrials |
| NCT05114213 | MR-Guided Adaptive SBRT of Primary Tumor for Pain Control in Metastatic PDAC(MASPAC) | terminated | Phase 2 | 9 | Ludwig-Maximilians - University of MunichOTHER | 2 | Dec 5, 2025 | clinicaltrials |
| NCT02066220 | International Society of Paediatric Oncology (SIOP) PNET 5 Medulloblastoma | active not recruiting | Phase 2 / Phase 3 | 360 | Universitätsklinikum Hamburg-EppendorfOTHER | 16 | Dec 4, 2025 | clinicaltrials |
| NCT03300492 | Expanded Natural Killer Cells Following Haploidentical HSCT for AML/MDS | recruiting | Phase 1 / Phase 2 | 10 | University Hospital, Basel, SwitzerlandOTHER | 1 | Dec 4, 2025 | clinicaltrials |
| NCT06126731 | Combination Study of Antibiotics With Enzalutamide (PROMIZE) | recruiting | Phase 1 / Phase 2 | 39 | Institute of Cancer Research, United KingdomOTHER | 2 | Nov 24, 2025 | clinicaltrials |
| NCT03498521 | A Phase II Randomized Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site(CUPISCO) | completed | Phase 2 | 529 | Hoffmann-La RocheINDUSTRY | 33 | Nov 19, 2025 | clinicaltrials |
| NCT06455917 | TIL Therapy in Non-small-cell Lung Cancer (NSCLC) Patients(BaseTIL-02L) | recruiting | Phase 2 | 30 | University Hospital, Basel, SwitzerlandOTHER | 1 | Nov 19, 2025 | clinicaltrials |
| NCT03011372 | A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement - (FIGHT-203) | completed | Phase 2 | 47 | Incyte CorporationINDUSTRY | 11 | Nov 18, 2025 | clinicaltrials |
| NCT04549428 | Atezolizumab Plus 8 Gy Single-fraction Radiotherapy for Advanced Oligoprogressive NSCLC | terminated | Phase 2 | 12 | Oncology Institute of Southern SwitzerlandOTHER | 1 | Nov 18, 2025 | clinicaltrials |
| NCT05748145 | Metronidazole as Preoperative Therapy in CRC / FusoMetro-001 | recruiting | Phase 2 | 40 | Oncology Institute of Southern SwitzerlandOTHER | 1 | Nov 18, 2025 | clinicaltrials |
| NCT03539536 | Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treated c-Met+ Non-Small Cell Lung Cancer | active not recruiting | Phase 2 | 270 | AbbVieINDUSTRY | 26 | Nov 5, 2025 | clinicaltrials |
| NCT03822117 | Efficacy and Safety of Pemigatinib in Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207) | terminated | Phase 2 | 111 | Incyte CorporationINDUSTRY | 11 | Nov 4, 2025 | clinicaltrials |
| NCT02572843 | Anti-PD-L1 in Stage IIIA(N2) Non-small Cell Lung Cancer (NSCLC) | completed | Phase 2 | 68 | Swiss Cancer InstituteOTHER | 1 | Oct 28, 2025 | clinicaltrials |
| NCT04700072 | Substudy 02D: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Melanoma Brain Metastasis (MK-3475-02D/KEYMAKER-U02) | completed | Phase 1 / Phase 2 | 56 | Merck Sharp & Dohme LLCINDUSTRY | 8 | Oct 28, 2025 | clinicaltrials |
| NCT04402073 | Personalized Risk-Adapted Therapy in Post-Pubertal Patients With Newly-Diagnosed Medulloblastoma(PersoMed-I) | terminated | Phase 2 | 20 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 8 | Oct 23, 2025 | clinicaltrials |
| NCT05694013 | Clinical Impact and Utility of Digital Health Solutions in Participants Receiving Systemic Treatment in Clinical Practice(ORIGAMA) | terminated | Phase 2 / Phase 3 | 49 | Hoffmann-La RocheINDUSTRY | 5 | Oct 22, 2025 | clinicaltrials |
| NCT04838626 | Study of Diagnostic Performance of [18F]CTT1057 for PSMA-positive Tumors Detection(GuideView) | completed | Phase 2 / Phase 3 | 195 | Novartis PharmaceuticalsINDUSTRY | 5 | Oct 7, 2025 | clinicaltrials |
| NCT04472949 | Thoracic Radiotherapy Plus Maintenance Durvalumab After First Line Carboplatin and Etoposide Plus Durvalumab in Extensive-stage Disease Small Cell Lung Cancer (ED-SCLC). | active not recruiting | Phase 2 | 46 | Swiss Cancer InstituteOTHER | 1 | Oct 1, 2025 | clinicaltrials |
| NCT03731260 | (PIONEER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, Versus Placebo in Patients With Indolent Systemic Mastocytosis | active not recruiting | Phase 2 | 251 | Blueprint Medicines CorporationINDUSTRY | 13 | Sep 23, 2025 | clinicaltrials |
| NCT04258943 | Bosutinib in Pediatric Patients With Newly Diagnosed Chronic Phase or Resistant/Intolerant Ph + Chronic Myeloid Leukemia | active not recruiting | Phase 1 / Phase 2 | 60 | Children's Oncology GroupNETWORK | 8 | Sep 18, 2025 | clinicaltrials |
| NCT05658640 | HEM iSMART-D: Trametinib + Dexamethasone + Chemotherapy in Children With Relapsed or Refractory Hematological Malignancies(HEM-iSMART D) | recruiting | Phase 1 / Phase 2 | 26 | Princess Maxima Center for Pediatric OncologyOTHER | 15 | Sep 16, 2025 | clinicaltrials |
| NCT02923349 | A Phase 1/2, Open-Label, Dose-Escalation, Safety Study of INCAGN01949 in Subjects With Advanced or Metastatic Solid Tumors | completed | Phase 1 / Phase 2 | 87 | Incyte Biosciences International SàrlINDUSTRY | 4 | Aug 24, 2025 | clinicaltrials |
| NCT03322540 | Pembrolizumab Plus Epacadostat vs Pembrolizumab Plus Placebo in Metastatic Non-Small Cell Lung Cancer (KEYNOTE-654-05/ECHO-305-05) | completed | Phase 2 | 154 | Incyte CorporationINDUSTRY | 18 | Aug 22, 2025 | clinicaltrials |
| NCT04023526 | A Study of Cusatuzumab Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia Who Are Not Candidates for Intensive Chemotherapy(CULMINATE) | active not recruiting | Phase 2 | 103 | OncoVerity, Inc.INDUSTRY | 9 | Aug 20, 2025 | clinicaltrials |
| NCT04910022 | Ph I/II Study of NMS-03305293+TMZ in Adult Patients With Recurrent Glioblastoma | active not recruiting | Phase 1 / Phase 2 | 150 | Nerviano Medical SciencesINDUSTRY | 5 | Aug 19, 2025 | clinicaltrials |
| NCT03620669 | 1st Line Durvalumab in PS 2 NSCLC Patients | active not recruiting | Phase 2 | 48 | Swiss Cancer InstituteOTHER | 1 | Aug 15, 2025 | clinicaltrials |
| NCT03599713 | A Study of INCMGA00012 in Metastatic Merkel Cell Carcinoma (POD1UM-201) | completed | Phase 2 | 107 | Incyte CorporationINDUSTRY | 12 | Aug 5, 2025 | clinicaltrials |
| NCT05403385 | Study of Inupadenant (EOS100850) With Chemotherapy as Second Line Treatment for Nonsquamous Non-small Cell Lung Cancer | active not recruiting | Phase 2 | 36 | iTeos TherapeuticsINDUSTRY | 8 | Aug 3, 2025 | clinicaltrials |
| NCT02278796 | A Trial Comparing the Two High-dose Chemotherapies BeEAM and BEAM Given Before Autologous Stem Cell Transplantation (ASCT) in Lymphoma Patients (BEB-trial)(BEB) | completed | Phase 2 | 108 | Insel Gruppe AG, University Hospital BernOTHER | 2 | Aug 1, 2025 | clinicaltrials |
Data updated 22 days agoSource updated unknownsource: clinicaltrials